Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T.

Journal of neurochemistry - 1 Jul 2008

Gerard Melanie, Debyser Zeger, Desender Linda, Baert Johan, Brandt Inger, Baekelandt Veerle, Engelborghs Yves

Abstract excerpt

Aggregation of alpha-synuclein (alpha-SYN) plays a key role in Parkinson's disease. We have previously shown that aggregation of alpha-SYN in vitro is accelerated by addition of FK506 binding proteins (FKBP) and that this effect can be counteracted by FK506, a specific inhibitor of these enzymes. In this paper, we investigated in detail the effect of FKBP12 on early aggregation and on fibril formation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Catalytic Domain

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Nerve Degeneration

Share to Neurofibrillary Tangles

Share to Nonlinear Dynamics

Share to Parkinson Disease

Share to Tacrolimus

Source

Identifiers

PMID: 18346205
DOI: 10.1111/j.1471-4159.2008.05342.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T.PMID 18346205Read ↗

Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.Semantic proximity Read ↗

Peptidyl-prolyl isomerase activity of FK506 binding protein 12 prevents tau peptide from aggregating.Semantic proximity Read ↗

Kinetics of protein fibril formation: Methods and mechanisms.Semantic proximity Read ↗

Amyloidogenic 60-71 deletion/ValThr insertion mutation of apolipoprotein A-I generates a new aggregation-prone segment that promotes nucleation through entropic effects.Semantic proximity Read ↗

Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.Semantic proximity Read ↗

Conformational switch of polyglutamine-expanded huntingtin into benign aggregates leads to neuroprotective effect.Semantic proximity Read ↗

Mechanisms of enhanced aggregation and fibril formation of Parkinson's disease-related variants of α-synuclein.Semantic proximity Read ↗

Mechanistic Models of Protein Aggregation Across Length-Scales and Time-Scales: From the Test Tube to Neurodegenerative DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.